The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2018 | The importance of AML education amongst practitioners
A large proportion of acute myeloid leukemia (AML) patients are treated by non-specialist community oncologists, who may not have the time or energy to attend conferences or lectures presenting specialized AML research. We interviewed Naval Daver, MD, of MD Anderson Cancer Center, Houston, TX, at the 23rd Congress of the European Hematological Association (EHA) 2018 in Stockholm, Sweden about the importance of creating new, easy-access platforms for AML education, such as VJHemOnc. He discusses the benefits of such platforms, along with a few of the dangers that may be accompanied by poor knowledge of the newest AML treatments and research.
